Ensoma
Ensoma is a biotechnology company developing one-time, in vivo genomic medicines. Its lead product, EN-374, targets X-linked chronic granulomatous disease.
Secondary Market Price
How Ensoma Measures Up
To help you manage your Ensoma equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Ensoma's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Ensoma Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Ensoma's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Ensoma is a biotechnology research company based in Boston, MA, that develops one-time, in vivo treatments designed to engineer blood and immune cells. The company's work is centered on genomic medicine, with a current focus on creating off-the-shelf therapies. One of its leading programs is EN-374, an in vivo HSC-directed gene insertion therapy for X-linked chronic granulomatous disease, which is currently in a multinational Phase 1/2 clinical trial. The company's name is derived from the Greek phrase 'en soma,' meaning 'in the body,' reflecting its therapeutic approach. Ensoma has progressed from its initial stages to become a clinical-stage company, a key milestone marked by the initiation of its EN-374 trial.
Looking ahead, Ensoma aims to advance its pipeline of off-the-shelf therapies and expects to have its first CAR-M, NK & T candidate ready in early 2025. The company's recent progress includes several significant developments. In late 2025, the U.K. Medicines and Healthcare Products Regulatory Agency cleared its clinical trial application for EN-374, shortly after the first patient was dosed in the study. The company also received the BioTech Breakthrough Award for Gene Editing Platform of the Year and presented preclinical data for its in vivo, HSC-derived CAR-M, NK & T platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
- 5AM Ventures
- Arix Bioscience
- F-Prime Capital
- Cormorant Asset Management
- Viking Global Investors
- Takeda Ventures
- SymBiosis
- Alexandria Venture Investments
- Fred Hutchinson Cancer Center
- Bill & Melinda Gates Foundation
- Qatar Investment Authority
- Solasta Ventures
- Catalio Capital Management
- Mirae Asset
- Kite, a Gilead Company
- Bioluminescence Ventures
- Delos Capital
- Co-Founder, Hans-Peter Kiem
- Co-Founder, André Lieber
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Ensoma worth joining?
Deciding if a company is worth joining depends on many factors, including the potential value of its equity compensation. Tools like Prospect can help you analyze the risk and reward of a stock option grant to make a more informed career decision.
What should I do with my Ensoma stock?
Managing private company stock requires a clear strategy for when to exercise options and how to plan for taxes. Platforms like Prospect use your financial details to build a personalized plan, helping you maximize the value of your equity.
Can you sell Ensoma stock?
Selling stock in a private company is typically possible during specific liquidity events, such as a tender offer or secondary sale. When these opportunities arise, Prospect's tender offer tools can help you determine how much to sell and which shares are the most tax-optimal.
How can I find the value of my Ensoma stock?
Valuing private stock is difficult because it doesn't trade on a public market, but you can use data to create an estimate. Prospect's predictive models analyze data points like funding rounds and secondary market prices to project the future value of your shares.
What is Ensoma's equity worth?
The ultimate worth of your equity depends on the company's success and your strategy for managing taxes and exercise costs. To understand its potential net value, you can use platforms like Prospect, which model outcomes to help you see what your stake could be worth after taxes and fees.
What is Ensoma's stock ticker symbol?
As a private company, Ensoma is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell Ensoma stock?
You can typically "buy" stock by exercising your employee stock options, and you can sell it during company-approved liquidity events like tender offers. Prospect provides strategies to help you decide the optimal time to both exercise your options and sell your shares.
What is the criteria to buy or invest in Ensoma stock?
Investing in a private company like Ensoma is generally restricted to employees who receive equity grants or accredited investors participating in organized funding rounds. The general public cannot typically buy shares until the company goes public.
